Email Updates

Search form

You are here

AVAC in the News

  • Last week, 2,499 gay and bisexual men and transgender women from four continents made history when the iPrEx HIV prevention trial reported positive results.

    December 10, 2010
    Huffington Post
  • In the study, published Tuesday by the New England Journal of Medicine, researchers found that the men taking Truvada, a common combination of two antiretroviral drugs, were 44 percent less likely to get infected with the virus that causes AIDS than an equal number taking a placebo.

    November 23, 2010
    New York Times
  • In the next few months, said Mitchell Warren, executive director of AVAC, an advocacy group for AIDS prevention, “we’re going to see a cascade of results” from trials of what is called “oral pre-exposure prophylaxis,” or “oral prep” for short. In them, men and women who are not infected with the AIDS virus but who regularly engage in high-risk sex, like anal sex without condoms or sex for money with strangers, take a daily dose of one or two of the antiretroviral drugs normally taken by infected people.

    November 8, 2010
    New York Times
  • Mitchell Warren, executive director of global advocacy organisation AVAC, said: "Not only is South Africa at the forefront of testing individual approaches but it is leading the development of combination prevention, which is clearly the only way to truly end the epidemic."

    May 26, 2010
    Times (South Africa)
  • This year, for the first time, we mark the Day with hope based on evidence from a trial in humans that shows that an AIDS vaccine is possible.

    May 17, 2010
    Huffington Post
  • The microbicides field has undoubtedly moved and shifted a lot in the past decade. Now, with first generation microbicides candidate products up and gone, antiretroviral treatment (ART)-drug based microbicides in spotlight, and only three major microbicides efficacy studies remaining, the need to lobby for increased funding of microbicides research and development, was never so compelling.

    May 14, 2010
    Citizen News Service
  • Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place. The approach may help curb the AIDS pandemic in poor countries and bring Gilead $1 billion a year in additional U.S. sales, said Josh Schimmer, an analyst at Leerink Swann & Co. in Boston. Most investors aren’t alert to the potential benefit, he said. Researchers are compiling the first data from 10 trials involving more than 20,000 people, and initial results may be available in July.

    April 1, 2010
  • Researchers said the failure of the microbicide gels in a trial in South Africa, Zambia, Uganda and Tanzania was the last nail in the coffin for this type of prevention method.

    December 15, 2009
    New York Times
  • An antimicrobial gel tested as a method to curb the spread of HIV just proved ineffective in a major human study.

    December 14, 2009
  • A decade of increasing funding for HIV programs - in prevention, treatment and research - is paying off. Ironically, though, this good news comes at the same time that the global economic crisis and political arguments threaten the future of HIV funding.

    November 30, 2009
    Huffington Post